search
Back to results

Cerclage vs Cervical Pessary in Women With Cervical Incompetence (CEPEIC)

Primary Purpose

Cervical Insufficiency

Status
Completed
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Cerclage
Cervical pessary
Sponsored by
Maternal-Infantil Vall d´Hebron Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cervical Insufficiency focused on measuring cervical insufficiency, cervical cerclage, cervical pessary

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Singleton pregnancy
  • Minimum age: 18 years
  • Previous PB based on CI (primary intervention, <16 weeks) or in case of previous PB and a short cervical length in current pregnancy ≤ 25 mm (secondary intervention, <24 weeks). Women are randomised (1:1) either to cervical cerclage or pessary treatment.

Exclusion Criteria:

  • Major fetal abnormalities (requiring surgery or leading to infant death or severe handicap)
  • Threatened preterm labour at time of randomization
  • Spontaneous rupture of membranes at time of randomization
  • Chorioamnionitis at time of randomization
  • Active vaginal bleeding
  • Placenta previa

Sites / Locations

  • Hospital Vall d'Hebron

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Cerclage

Cervical pessary

Arm Description

Cervical cerclage.

Cervical pessary

Outcomes

Primary Outcome Measures

Spontaneous delivery before 34 complete weeks
Spontaneous delivery before 34 complete weeks

Secondary Outcome Measures

Spontaneous delivery before 28 complete weeks
Spontaneous delivery before 28 complete weeks
Spontaneous delivery before 37 complete weeks
Spontaneous delivery before 37 complete weeks
Foetal and neonatal death
Foetal and neonatal death
Neonatal morbidity
Neonatal morbidity
Maternal side effects
Maternal side effects
Maternal morbidity
Maternal morbidity
Number of participants with chorioamnionitis infection
Number of participants with chorioamnionitis infection
Hospitalisation for threatened preterm labour
Hospitalisation for threatened preterm labour

Full Information

First Posted
March 16, 2015
Last Updated
March 16, 2021
Sponsor
Maternal-Infantil Vall d´Hebron Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT02405455
Brief Title
Cerclage vs Cervical Pessary in Women With Cervical Incompetence
Acronym
CEPEIC
Official Title
Cerclage vs Cervical Pessary in Women With Cervical Incompetence
Study Type
Interventional

2. Study Status

Record Verification Date
March 2021
Overall Recruitment Status
Completed
Study Start Date
June 2015 (undefined)
Primary Completion Date
March 2021 (Actual)
Study Completion Date
March 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Maternal-Infantil Vall d´Hebron Hospital

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Cervical insufficiency (CI), responsible for 8% of preterm births (PB), is used to describe painless cervical dilation leading to recurrent second-trimester pregnancy losses/births of otherwise normal pregnancies. Structural weakness of cervical tissue was thought to cause or contribute to these adverse outcomes. The term has also been applied to women with one or two such losses/births or at risk for second-trimester pregnancy loss/birth. Cervical pessary and cervical cerclage are both considered as preventive treatments in women at risk for PB. This study aims to demonstrate that the cervical pessary could reduce the preterm birth rate before 37 weeks of gestation in women with prior PB due to cervical insufficiency or in women with prior PB and a short cervix in the current pregnancy.
Detailed Description
Methods/Design: This is an open-label, pilot, multicentre, prospective, randomised controlled trial (RCT). Enrolees are women with singleton pregnancies and previous PB based on CI (primary intervention, <16 weeks) or in case of previous PB and a short cervical length in current pregnancy ≤ 25 mm (secondary intervention, <24 weeks). Women are randomised (1:1) either to cervical cerclage or pessary treatment. The primary outcome is the spontaneous preterm birth rate before 34 weeks of gestation. The sample size was calculated, as a pilot study, based on the estimated population that we will be able to recruit during the duration of the trial: 60 women, 30 for each group (cervical cerclage and cervical pessary group) to observe, at least a reduction in the PB rate < 34 weeks from 34% to 27% in the pessary group, as does cerclage. Discussion: The outcome of this study will show the effectiveness of a cervical cerclage and of a cervical pessary in this group of patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cervical Insufficiency
Keywords
cervical insufficiency, cervical cerclage, cervical pessary

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Cervical pessary vs. Cervical cerclage
Masking
None (Open Label)
Allocation
Randomized
Enrollment
60 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Cerclage
Arm Type
Experimental
Arm Description
Cervical cerclage.
Arm Title
Cervical pessary
Arm Type
Experimental
Arm Description
Cervical pessary
Intervention Type
Procedure
Intervention Name(s)
Cerclage
Intervention Description
Surgical procedure which consists of a strong suture being inserted into and around the cervix to close it.
Intervention Type
Device
Intervention Name(s)
Cervical pessary
Intervention Description
The Arabin cervical pessary, which is CE-certified for preventing spontaneous preterm birth (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC). It is a vaginal device which is used to treat pregnant women for preventing spontaneous preterm birth. This device can be easily placed around the uterine cervix without pain.
Primary Outcome Measure Information:
Title
Spontaneous delivery before 34 complete weeks
Description
Spontaneous delivery before 34 complete weeks
Time Frame
Before 34 weeks of gestation
Secondary Outcome Measure Information:
Title
Spontaneous delivery before 28 complete weeks
Description
Spontaneous delivery before 28 complete weeks
Time Frame
Before 28 weeks of gestation
Title
Spontaneous delivery before 37 complete weeks
Description
Spontaneous delivery before 37 complete weeks
Time Frame
Before 37 weeks of gestation
Title
Foetal and neonatal death
Description
Foetal and neonatal death
Time Frame
During pregnancy and during the first 28 days of newborn or NICU stay
Title
Neonatal morbidity
Description
Neonatal morbidity
Time Frame
28 days of newborn or during NICU stay
Title
Maternal side effects
Description
Maternal side effects
Time Frame
During pregnancy
Title
Maternal morbidity
Description
Maternal morbidity
Time Frame
during pregnancy
Title
Number of participants with chorioamnionitis infection
Description
Number of participants with chorioamnionitis infection
Time Frame
During pregnancy
Title
Hospitalisation for threatened preterm labour
Description
Hospitalisation for threatened preterm labour
Time Frame
During pregnancy

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Singleton pregnancy Minimum age: 18 years Previous PB based on CI (primary intervention, <16 weeks) or in case of previous PB and a short cervical length in current pregnancy ≤ 25 mm (secondary intervention, <24 weeks). Women are randomised (1:1) either to cervical cerclage or pessary treatment. Exclusion Criteria: Major fetal abnormalities (requiring surgery or leading to infant death or severe handicap) Threatened preterm labour at time of randomization Spontaneous rupture of membranes at time of randomization Chorioamnionitis at time of randomization Active vaginal bleeding Placenta previa
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Maria Goya, PhD
Organizational Affiliation
Hospital Vall d'Hebrón
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Andrea Gascón, MD
Organizational Affiliation
Hospital Vall d'Hebrón
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital Vall d'Hebron
City
Barcelona
ZIP/Postal Code
08035
Country
Spain

12. IPD Sharing Statement

Learn more about this trial

Cerclage vs Cervical Pessary in Women With Cervical Incompetence

We'll reach out to this number within 24 hrs